Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877) has released an update.
Shanghai Junshi Biosciences has decided to use approximately RMB189.769 million of its remaining surplus proceeds to permanently replenish its liquidity, effectively bringing the balance of its surplus proceeds account to zero. This financial maneuver, approved by the board and verified by Haitong Securities, demonstrates Junshi Biosciences’ strategic management of its resources to bolster financial stability.
For further insights into HK:1877 stock, check out TipRanks’ Stock Analysis page.